Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection

DOYUK KARTAL E., NAYMAN ALPAT S., Ozgunes I., USLUER G.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.19, sa.9, ss.817-820, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 9
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1097/meg.0b013e32818b27e5
  • Dergi Adı: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.817-820
  • Anahtar Kelimeler: alopecia, chronic hepatitis C, interferon, ribavirin, side effects, ALPHA PLUS RIBAVIRIN, INTERFERON-ALPHA, AREATA, PREVALENCE, MANAGEMENT, CYTOKINES, TOTALIS, IFN
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Combined treatment with pegylated interferon (PEG-IFN) and ribavirin is currently recommended for the treatment of chronic hepatitis C virus (HCV) infection. Many side effects including hair disorders have, however, been reported related to this treatment. Alopecia universalis is a severe form of hair disorder. Three cases of alopecia universalis during PEG-IFN and ribavirin combination therapy have been reported in the literature. Herein is reported a case of reversible alopecia universalis, with complete hair loss extending to the whole body, secondary to PEG-IFN alpha-2b and ribavirin combination therapy for chronic HCV infection. Hair regrowth began within 3 months of the completion of combined therapy. In case the liver disease is advanced, and virologic response occurs, treatment can still be completed, as it appears that these side effects are reversible.